Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma

IntroductionCombination immunotherapy with ipilimumab and nivolumab has improved long-term progression-free and overall survival in patients with metastatic melanoma. Unfortunately, a high percentage of patients develop immune-related side effects, including endocrinopathy. The incidence and timing...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Mahir Hasan, Wolfram Samlowski, Samer Nakhle
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2026-05-01
Serija:	Frontiers in Endocrinology
Teme:	cancer immunotherapy checkpoint inhibitors endocrinopathy hypophysitis hypothyroidism progression-free survival
Online dostop:	https://www.frontiersin.org/articles/10.3389/fendo.2026.1827644/full
Oznake:	Označite Brez oznak, prvi označite!